期刊文献+

血清CA724、CYFRA21-1及PIVKA-Ⅱ诊断卵巢癌价值 被引量:12

Analysis of the value of serum CA724, CYFRA21-1 and PIVKA- II levels for diagnosing patients with ovarian cancer
下载PDF
导出
摘要 目的:探讨血清糖类抗原724(CA724)、细胞角蛋白19片断(CYFRA21-1)及异常凝血酶原(PIVKA-Ⅱ)在诊断卵巢癌的应用价值。方法:选取本院肿瘤科收治的卵巢癌患者46例作为卵巢癌组,卵巢良性肿瘤患者50例为良性肿瘤组,健康体检50例为健康对照组,采用化学发光法检测血清CA724、CYFRA21-1、PIVKA-Ⅱ水平,绘制受试者工作者特征曲线(AUC)比较分析。结果:血清CA724、CYFRA21-1、PIVKA-Ⅱ水平及组内阳性率卵巢癌组>良性肿瘤组>对照组(P<0.05);CA724的AUC为0.845,诊断敏感性为72.1%,特异性为87.9%;CYFRA21-1的AUC为0.813,诊断敏感性为67.4%,特异性为83.5%;PIVKA-Ⅱ的AUC为0.729,临界值为>24.74 U/L,诊断敏感性为61.4%,特异性为91.0%;CA724+CYFRA21-1、CA724+PIVKA-Ⅱ、CYFRA21-1+PIVKA-Ⅱ两两联合诊断卵巢癌的阳性率均较高(81.6%、82.6%、82.2%),但CA724+CYFRA21-1检测灵敏度、诊断准确率高于其他两组,3项指标联合检测的灵敏度、阳性率、诊断准确率最高,且特异性未见明显降低。结论:血清CA724、CYFRA21-1、PIVKA-Ⅱ对卵巢癌具有较高的辅助诊断价值,且三者联合检测可提高卵巢癌阳性检出率。 Objective:To investigate the value of serum levels of carbohydrate antigen 724(CA724),cytokeratin 19 fragment(CYFRA21-1)and abnormal prothrombin(PIVKA-II)for diagnosing patients with ovarian cancer.Methods:46 patients with ovarian cancer were selected in study group,50 patients with benign ovarian tumor were selected in control group,and 50 healthy women were elected in healthy control group.The levels of serum CA724,CYFRA21-1 and PIVKA-II were detected by chemiluminescence.The area under curve(AUC)of receiver operator characteristic was used for analyzing the value of levels of serum CA724,CYFRA21-1 and PIVKA-II.Results:The levels of serum CA724,CYFRA21-1 and PIVKA-II of patients in study group were the highest among the three groups,but were the lowest in healthy control group(P<0.05).The value of AUC,the sensitivity and the specificity of CA724 level were 0.845,72.1%,and 87.9%,respectively,the value of AUC,the sensitivity and the specificity of CYFRA21-1 level were 0.813,67.4%,and 83.5%,respectively,and the value of AUC,the sensitivity and the specificity of PIVKA-II were 0.729,61.4%,and 91.0%,respectively.The critical value of CYFRA21-1 level was over 24.74 U/L.And the diagnosis positive rates of A724 level combined with CYFRA21-1 level,CA724 level combined with PIVKA-II level,CYFRA21-1 level combined with PIVKA-II level combined detections were 81.6%,82.6%,and 82.2%,respectively.The sensitivity and accuracy of CA724 level combined with CYFRA21-1 level were higher than those of CA724 level combined with PIVKA-II level or CYFRA21-1 level combined with PIVKA-II level.The sensitivity,positive rate and diagnostic accuracy of the combination of CA724 level,CYFRA21-1 level and PIVKA-II level had increased significantly,while the specificity hadn’t decreased.Conclusion:Serum CA724,CYFRA21-1and PIVKA-II levels have high value for diagnosing ovarian cancer,and the combination of the Serum CA724,CYFRA21-1and PIVKA-II levels can increase the positive rate of ovarian cancer diagnosed significantly.
作者 胡薇 徐鸿绪 陈启斌 李琳 刘茜 吴萍 HU Wei;XU Hongxu;CHEN Qibin;LI Lin;LIU Qian;WU Ping(Shunde Hospital of Guangzhou University of Chinese Traditional Medicine,Guangdong Province,528300;The First Hospital Affiliated to Sun Yat-sen University;The First People's Hospital of Zhaotong City of Yunnan Province)
出处 《中国计划生育学杂志》 2019年第2期230-233,共4页 Chinese Journal of Family Planning
关键词 卵巢癌 糖类抗原724 细胞角蛋白19片断 异常凝血酶原 检测价值分析 Ovarian cancer Carbohydrate antigen 724 Cytokeratin 19 fragment Abnormal prothrombin Value analysis
  • 相关文献

参考文献11

二级参考文献118

  • 1Yoshihisa Takahashi,Tohru Inoue,Toshio Fukusato.Protein induced by vitamin K absence or antagonist Ⅱ-producing gastric cancer[J].World Journal of Gastrointestinal Pathophysiology,2010,1(4):129-136. 被引量:4
  • 2李丽(综述),吴青青,(审校),谢玉娴(审校).应用超声鉴别卵巢肿瘤良恶性的研究进展[J].临床超声医学杂志,2006,8(6):363-365. 被引量:5
  • 3胡菱凤,蒋敬庭,邓海峰,陆明洋,徐斌.血清TSGF与SCCAg及CYFRA211检测对鼻咽癌的诊断价值[J].中华肿瘤防治杂志,2007,14(24):1894-1895. 被引量:5
  • 4Oberaigner W, Minicozzi P, Bielska-Lasota M,et al. Survial for ovari- an cancer in Europe: the across-country did not shrink in the past dec- ade[J]. Acta Oneol, 2012, 51(4) :441-453.
  • 5Moore RG, MaeLanghlan S, Bast Re Jr. Current state of biomarket de- velopment for clinical application in epithelial ovarian cancer [Jl. Gy- neeol Oncol, 2010, 116(2) :240-245.
  • 6Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of bio- marker panels for early stage ovarian cancer detection and monitoring for disease recurrence[ J]. Gynecol Oncol, 2008, 110(3 ) :374-382.
  • 7Karolina P, Bjorg K J, Karin S, et al. Evaluation of ovarian cancer bi- omarkers HE4 and CA-125 in women presenting with a suspicious cyst- ic ovarian mass[J]. J Gynecol Oneol, 2011, 22(4) :244-252.
  • 8Brechot JM, Chevret S, Natal" J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumor markers in patients with non- small lung cancer: a prospective study of 116 patients [J]. Eur J Cancer, 1997, 33(3) :385-391.
  • 9Kawai M, Kano T, Kikkawa F, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary [ Jl. Gynecol Oncol, 1992, 45(3) :248-253.
  • 10Fioretti P, Gaddueci A, Ferdeghini M, et al. The concomitant deter- mination of different serum tumor markers in epithelial ovarian cancer: relewanee for monitoring the response to chemotherapy and follow-up of patients[J]. Gyneeol Oneol, 1992, 44(2) :155-160.

共引文献110

同被引文献121

引证文献12

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部